Compare RLJ & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLJ | MPLT |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2011 | 2025 |
| Metric | RLJ | MPLT |
|---|---|---|
| Price | $11.42 | $11.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $7.83 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 05-04-2026 | 05-28-2026 |
| Dividend Yield | ★ 7.26% | N/A |
| EPS Growth | N/A | ★ 82.39 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,349,860,000.00 | N/A |
| Revenue This Year | $2.02 | N/A |
| Revenue Next Year | $2.54 | N/A |
| P/E Ratio | $95.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.54 | $9.10 |
| 52 Week High | $12.89 | $40.43 |
| Indicator | RLJ | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 29.77 |
| Support Level | $10.86 | $10.83 |
| Resistance Level | $12.11 | $20.20 |
| Average True Range (ATR) | 0.39 | 0.94 |
| MACD | -0.04 | 0.52 |
| Stochastic Oscillator | 32.81 | 12.20 |
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.